EGFR and non-small cell lung carcinoma: In a preliminary report of the ONCOBELL trial currently being conducted in Italy [41], response rate to gefitinib was 68% in the EGFR-FISH positive and 9% in the EGFR FISH negative NSCLC patients (p < 0.001).